- Skingenix, Inc. announces treatment of the first patient with investigational drug, MW-III in adult patients with Second-Degree Thermal Burns in USA. (2/4/2023) - On 02 February 2023, in a Phase II, Open-Label, Randomized, Active-Controlled Pilot Study, the first patient was successfully treated with Skingenix’s investigational drug, MW-III by the investigator Jeffrey Shupp, MD, at MedStar Washington Hospital Center, in USA. This clinical study is currently ongoing, in which a total of 60 patients with Second-Degree Thermal Burns, will […]
- Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study (12/30/2013) - Skingenix, Inc. announces successful completion of a Phase II, Randomized, Controlled, Multi-Center Study to assess the Safety and Efficacy of their investigational product in patients with Diabetic Foot Ulcers. This clinical study was completed in December 2013 , more information can be found at www.clinicaltrials.gov
- Skingenix, Inc. announces treatment of the first patient with the investigational product in patients with Diabetic Foot Ulcers in USA. (8/9/2012) - On 9 October 2012, in a Phase II randomized and controlled multicenter clinical trial, the first subject was successfully treated with Skingenix’s investigational product in USA. This clinical study is currently ongoing, in which a total of 35 patients with Diabetic Foot Ulcers will be treated with the investigational product. The study is currently recruiting eligible […]
- Skingenix, Inc. announces completion of two pilot clinical studies with the investigational product in patients with Venous Leg Ulcers and Diabetic Foot Ulcers in USA. (12/30/2011) - Under an Investigational New Drug Application (IND), Skingenix has successfully completed two pilot clinical studies in USA : First clinical study was conducted in patients with Venous Leg Ulcer. The second clinical study was conducted in patients with Diabetic Foot Ulcers. These studies were completed in December 2011.